Enter Wall Street with StreetInsider Premium. Claim your one week free trial here.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Chirfi Guindo will lead human health marketing as Chief Marketing Officer for Merck Human Health and will join Merck’s leadership team effective July 1, 2022. Guindo will report directly to Robert M. Davis, Chief Executive Officer and President of Merck. As previously announced, Jannie Oosthuizen runs Merck Human Health US, and Joe Romanelli will lead Merck Human Health International effective August 1, both also reporting to Davis. Deepak Khanna, acting director of Human Health International, will retire at the end of this year.
“Chirfi is a determined leader, dedicated to saving and improving lives around the world. He has deep experience and a proven track record in strategy, marketing and commercialization in primary care, specialty care and rare diseases, in both developed and developing markets,” said Davis. “I am confident that our human health leaders, along with our entire leadership team, will build on the strong momentum of our business as we deliver value to all of our stakeholders, continue to address some of the medical challenges most urgent and make a positive contribution and lasting impact on global health.
As Chief Marketing Officer for Human Health, Guindo will be responsible for leading the development and execution of the company’s long-term strategy for the human health portfolio spanning oncology, vaccines, pharmaceuticals and ongoing products.
Since 2017, Guindo has served as Executive Vice President and Head of Global Product Strategy and Commercialization at Biogen and served on Biogen’s leadership team. In this role, Guindo led the overall strategy, marketing and commercialization of Biogen’s neurology business. He also led the late-stage product development and go-to-market teams, and oversaw corporate strategy and alliances, value and access, communications, policy, advocacy and corporate accountability. company.
Prior to joining Biogen, Guindo began his career at Merck in 1990 and spent over 25 years in finance, sales, commercial and marketing roles of increasing responsibility in the United States and around the world. He led global marketing for Merck’s HIV portfolio and also led Merck’s human health businesses in Canada, the Netherlands and South Africa. Guindo was recognized for developing strong talent, forging innovative public-private partnerships and raising Merck’s profile as a patient-centric company. A graduate of Ecole Centrale de Paris with an engineering degree, he also holds a Master of Business Administration from New York University’s Stern School of Management.
At Merck, known as MSD outside the United States and Canada, we are united around our purpose: We use the power of cutting-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the world’s leading research-intensive biopharmaceutical company – and today we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of disease in humans and animals. We foster a diverse and inclusive global workforce and act responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com and join us on Twitter, Facebook, instagram, Youtube and LinkedIn.
Merck & Co., Inc., Rahway, NJ, USA Forward-Looking Statement
This press release from Merck & Co., Inc., Kenilworth, NJ, USA (the “Company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995 These statements are based on the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include, but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and around the world; global trends toward health care cost containment; technological advances, new products and patents obtained by competitors; challenges inherent in developing new products, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and exposure to litigation, including patent litigation, and/or regulatory actions.
The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Other factors that could cause results to differ materially from those described in the forward-looking statements can be found in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 and other company filings. with the Securities and Exchange Commission. (SEC) available on the SEC’s website (www.sec.gov).
Source: Merck & Co., Inc.